Inactive Instrument

PRIA ACQU Stock

PMGM

US74275N1028

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with a focus on the neurosciences market. ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. It has completed Phase II clinical study of ABP-450 for the treatment of cervical dystonia and has an ongoing Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.

Employees

Sector

More about the company

23-07-24	AEON Biopharma Completes Business Combination With Priveterra Acquisition; Shares Slump	MT
23-07-21	Priveterra Acquisition Completes Merger With AEON Biopharma	MT
23-07-21	Priveterra Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-07-21	Priveterra Acquisition Corp.(NasdaqCM:PMGM) dropped from NASDAQ Composite Index	CI
23-07-20	AEON Biopharma, Inc. completed the acquisition of Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.	CI
23-07-18	Priveterra Acquisition Gets New York Stock Exchange Approval for Listing of AEON Biopharma Stock, Warrants	MT
23-07-12	Priveterra Acquisition to Transfer Stock Listing to NYSE After Completing Business Combination	MT
23-07-05	Top Premarket Decliners	MT
23-05-17	Priveterra Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-04-26	Priveterra Acquisition Corp. announced that it has received $1 million in funding	CI
23-02-22	Priveterra Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-02-21	Priveterra Acquisition Corp. Auditor Raises 'Going Concern' Doubt	CI
22-12-12	AEON Biopharma, Inc. entered into a definitive business combination agreement to acquire Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.	CI

24-04-15	Priveterra Acquisition : SUPPLEMENTAL NOTICE OF REDEMPTION OF CERTAIN WARRANTS (CUSIP 00791X118) - Form 8-K	PU
23-07-24	AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update	AQ
23-07-21	Priveterra Acquisition Corp. Announces Completion of Business Combination with AEON Biopharma, Inc.	BU
23-07-17	Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.	BU
23-07-11	Priveterra Acquisition Corp. Announces Intention to Transfer to NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.	BU

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/21/23	Priveterra Sponsor LLC	Conversion	Company	6,900,000	100.0000%
7/3/23	Priveterra Sponsor LLC	Other	Company	6,900,000	100.0000%
2/8/21	Priveterra Sponsor LLC	Other	Company	6,900,000	100.0000%

PRIA ACQU Stock

Stocks

PMGM

US74275N1028

Latest news : PRIA ACQU

Press Releases: PRIA ACQU

Quotes and Performance

Latest insider transactions

Company Profile